Arbutus Biopharma (ABUS) Enterprise Value (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Enterprise Value for 17 consecutive years, with -$95.2 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 15.51% year-over-year to -$95.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$95.2 million (up 15.51% YoY) and the FY2025 annual result came in at -$91.5 million, up 25.4% from the prior year.
• Enterprise Value declined to -$95.2 million in Q1 2026 per ABUS's latest filing, from -$91.5 million in the prior quarter.
• Over the last five years, Enterprise Value for ABUS reached as high as -$91.5 million in Q4 2025 and fell as low as -$165.5 million in Q1 2022.
• A 5-year average of -$127.6 million and a median of -$129.2 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value sank 91.63% — and 2025, when it jumped 30.92%.
• Year by year, Enterprise Value stood at -$146.9 million in 2022, then rose by 14.23% to -$126.0 million in 2023, then advanced by 2.68% to -$122.6 million in 2024, then increased by 25.4% to -$91.5 million in 2025, then declined by 4.11% to -$95.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$95.2 million, -$91.5 million, and -$93.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.